Literature DB >> 25484035

Changes in neurocognition and adherence over six months in HIV-infected individuals with cocaine or heroin dependence.

Albert M Anderson1, Melinda K Higgins, Raymond L Ownby, Drenna Waldrop-Valverde.   

Abstract

We sought to examine the course of adherence and cognition in HIV-infected individuals with either cocaine or heroin dependence and investigate independent predictors of cognition change. A prospective study over six months was undertaken in which adherence was measured by monthly electronic pill cap monitoring (Medication Event Monitoring System), while a comprehensive neuropsychological battery resulting in a composite score (NPZ8) was performed at baseline and six months. Multivariable regression models were performed in order to determine independent associations with change in cognition. There were 101 subjects at baseline, of whom 62% were male and 83% were non-Hispanic black. 46.6% of subjects at baseline had completed high school, 36.6% reported active cocaine use during the course of the study, and 0% reported active heroin use during the course of the study. 66 subjects completed the final cognitive assessment at six months. Subjects had markedly impaired cognitive function at baseline (NPZ8 -1.49) which persisted at six months (NPZ8 -1.47) in the group of study completers. There was an average monthly decrease in adherence of -2.91% overall (p = 0.008). In the multivariable model, each of the following variables: baseline cognition (R(2) change = 0.121, p = 0.006), cocaine use during the study (R(2) change = 0.059, p = 0.046), and monthly adherence change (R(2) change = 0.078, p = 0.018) independently contributed to NPZ8 change with an overall R(2) change = 0.219 (p = 0.001). This study shows an overall decrease in adherence over time in this population of subjects with a history of drug dependence. Active cocaine use, baseline cognition, and temporal adherence changes independently contributed to changes in cognition. Further study on enhancing adherence, cognition, and limiting drug abuse are warranted in this subgroup of HIV-infected individuals.

Entities:  

Keywords:  HIV; HIV-associated neurocognitive disorder; adherence; cocaine; neurocognition

Mesh:

Substances:

Year:  2014        PMID: 25484035      PMCID: PMC4305469          DOI: 10.1080/09540121.2014.985183

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  9 in total

1.  Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users.

Authors:  Julia H Arnsten; Penelope A Demas; Richard W Grant; Marc N Gourevitch; Homayoon Farzadegan; Andrea A Howard; Ellie E Schoenbaum
Journal:  J Gen Intern Med       Date:  2002-05       Impact factor: 5.128

2.  Reciprocal prediction of medication adherence and neurocognition in HIV/AIDS.

Authors:  Mark L Ettenhofer; Jessica Foley; Steven A Castellon; Charles H Hinkin
Journal:  Neurology       Date:  2010-03-10       Impact factor: 9.910

Review 3.  Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder.

Authors:  Scott Letendre
Journal:  Top Antivir Med       Date:  2011-11

4.  Longitudinal change in cognitive function and medication adherence in HIV-infected adults.

Authors:  Brian W Becker; April D Thames; Ellen Woo; Steven A Castellon; Charles H Hinkin
Journal:  AIDS Behav       Date:  2011-11

5.  Testing an optimized community-based human immunodeficiency virus (HIV) risk reduction and antiretroviral adherence intervention for HIV-infected injection drug users.

Authors:  Michael M Copenhaver; I-Ching Lee; Arthur Margolin; Robert D Bruce; Frederick L Altice
Journal:  Subst Abus       Date:  2011-01       Impact factor: 3.716

6.  Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.

Authors:  Evan Wood; Julio S G Montaner; Benita Yip; Mark W Tyndall; Martin T Schechter; Michael V O'Shaughnessy; Robert S Hogg
Journal:  CMAJ       Date:  2003-09-30       Impact factor: 8.262

7.  Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users.

Authors:  Marianna K Baum; Carlin Rafie; Shenghan Lai; Sabrina Sales; Bryan Page; Adriana Campa
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

8.  Relationships among neurocognitive status, medication adherence measured by pharmacy refill records, and virologic suppression in HIV-infected persons.

Authors:  Adriana S A Andrade; Reena Deutsch; Shivaun A Celano; Nichole A Duarte; Thomas D Marcotte; Anya Umlauf; J Hampton Atkinson; J Allen McCutchan; Donald Franklin; Terry J Alexander; Justin C McArthur; Christina Marra; Igor Grant; Ann C Collier
Journal:  J Acquir Immune Defic Syndr       Date:  2013-03-01       Impact factor: 3.731

9.  Managed problem solving for antiretroviral therapy adherence: a randomized trial.

Authors:  Robert Gross; Scarlett L Bellamy; Jennifer Chapman; Xiaoyan Han; Jacqueline O'Duor; Steven C Palmer; Peter S Houts; James C Coyne; Brian L Strom
Journal:  JAMA Intern Med       Date:  2013-02-25       Impact factor: 21.873

  9 in total
  13 in total

1.  Rationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHRP-BB study.

Authors:  Roman Shrestha; Frederick L Altice; Brian Sibilio; Jude Ssenyonjo; Michael M Copenhaver
Journal:  Contemp Clin Trials       Date:  2019-06-20       Impact factor: 2.226

2.  Modeling a Theory-Based Approach to Examine the Influence of Neurocognitive Impairment on HIV Risk Reduction Behaviors Among Drug Users in Treatment.

Authors:  Tania B Huedo-Medina; Roman Shrestha; Michael Copenhaver
Journal:  AIDS Behav       Date:  2016-08

3.  Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment.

Authors:  Roman Shrestha; Pramila Karki; Frederick L Altice; Tania B Huedo-Medina; Jaimie P Meyer; Lynn Madden; Michael Copenhaver
Journal:  Drug Alcohol Depend       Date:  2017-02-02       Impact factor: 4.492

Review 4.  The impact of substance abuse on HIV-mediated neuropathogenesis in the current ART era.

Authors:  Vanessa Chilunda; Tina M Calderon; Pablo Martinez-Aguado; Joan W Berman
Journal:  Brain Res       Date:  2019-08-29       Impact factor: 3.252

5.  Comorbid mental health disorders in persons living with HIV: Adherence to antiretroviral therapy.

Authors:  Anna B Smith; Paul F Cook
Journal:  Arch Psychiatr Nurs       Date:  2019-04-19       Impact factor: 2.218

6.  Treatment Engagement Moderates the Effect of Neurocognitive Impairment on Antiretroviral Therapy Adherence in HIV-Infected Drug Users in Treatment.

Authors:  Roman Shrestha; Pramila Karki; Tania B Huedo-Medina; Michael Copenhaver
Journal:  J Assoc Nurses AIDS Care       Date:  2016-09-22       Impact factor: 1.354

7.  Examining the Acceptability of mHealth Technology in HIV Prevention Among High-Risk Drug Users in Treatment.

Authors:  Roman Shrestha; Tania B Huedo-Medina; Frederick L Altice; Archana Krishnan; Michael Copenhaver
Journal:  AIDS Behav       Date:  2017-11

8.  Methamphetamine compromises gap junctional communication in astrocytes and neurons.

Authors:  Paul Castellano; Chisom Nwagbo; Luis R Martinez; Eliseo A Eugenin
Journal:  J Neurochem       Date:  2016-04-18       Impact factor: 5.372

9.  Integrated Bio-behavioral Approach to Improve Adherence to Pre-exposure Prophylaxis and Reduce HIV Risk in People Who Use Drugs: A Pilot Feasibility Study.

Authors:  Roman Shrestha; Frederick L Altice; Pramila Karki; Michael M Copenhaver
Journal:  AIDS Behav       Date:  2018-08

Review 10.  An update on drug-drug interactions between antiretroviral therapies and drugs of abuse in HIV systems.

Authors:  Nuti Desai; Leah Burns; Yuqing Gong; Kaining Zhi; Asit Kumar; Nathan Summers; Santosh Kumar; Theodore J Cory
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-08-31       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.